Обострение ишемической болезни сердца: баланс риска болезни и риска лечения
- Авторы: Бражник В.А.1, Затейщиков Д.А.1
-
Учреждения:
- ГБУЗ Городская клиническая больница №51 Департамента здравоохранения г. Москвы
- Выпуск: Том 17, № 1 (2015)
- Страницы: 30-35
- Раздел: Статьи
- URL: https://bakhtiniada.ru/2075-1753/article/view/94217
- ID: 94217
Цитировать
Полный текст
Аннотация
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Виктория Алексеевна Бражник
ГБУЗ Городская клиническая больница №51 Департамента здравоохранения г. Москвыканд. мед. наук, главный врач ГБУЗ ГКБ №51 121309, Россия, Москва, ул. Алябьева, д. 7/33
Дмитрий Александрович Затейщиков
ГБУЗ Городская клиническая больница №51 Департамента здравоохранения г. Москвы
Email: dz@bk.ru
д-р мед. наук, проф., рук. первичного сосудистого отделения ГБУЗ ГКБ №51 121309, Россия, Москва, ул. Алябьева, д. 7/33
Список литературы
- A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998, 338 (21): 1498-505.
- Cannon C.P, Mc Cabe C.H, Wilcox R.G et al. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102 (2): 149-56.
- Mahaffey K.W, Wojdyla D.M, Carroll K et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2011; 124 (5): 544-54.
- Hurlen M, Abdelnoor M, Smith P et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347 (13): 969-74.
- Wallentin L, Wilcox R.G, Weaver W.D et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362 (9386): 789-97.
- Oldgren J, Budaj A, Granger C.B et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double - blind, phase II trial. Eur Heart J 2011; 32 (22): 2781-9.
- Douxfils J, Buckinx F, Mullier F et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all - cause mortality: a systematic review and meta - analysis of randomized controlled trials. J Am Heart Assoc 2014, 3 (3): e000515.
- Alexander J.H, Becker R.C, Bhatt D.L et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAI- SE) trial. Circulation 2009; 119 (22): 2877-85.
- Alexander J.H, Lopes R.D, James S et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365 (8): 699-708.
- Hess C.N, James S, Wojdyla D.M et al. Apixaban Plus Mono versus Dual Antiplatelet Therapy After Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial. Circulation 2014; 130 (Suppl. 2): A14643.
- Loke Y.K, Pradhan S, Yeong J.K, Kwok C.S. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta - analysis and adjusted indirect comparison. Br J Clin Pharmacol 2014; 78 (4): 707-17.
- Mega J.L, Braunwald E, Mohanavelu S et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double - blind, phase II trial. Lancet 2009; 374 (9683): 29-38.
- Mega J.L, Braunwald E, Wiviott S.D et al. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med 2012; 366 (1): 9-19.
- Mauri L, Kereiakes D.J, Yeh R.W et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med 2014; 371 (23): 2155-66.
- Reejhsinghani R, Lotfi A.S. Prevention of stent thrombosis: challenges and solutions. Vasc Health Risk Manag 2015; 11: 93-106.
- Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug - eluting stents. J Am Med Assoc 2005; 293 (17): 2126-30.
- Kohn C.G, Kluger J, Azeem M, Coleman C.I. Short - term consequences of angiographically - confirmed coronary stent thrombosis. PLoS One 2013; 8 (10): e77330.
- Cutlip D.E, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115 (17): 2344-51.
- Yadav M, Genereux P., Palmerini T et al. SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non-ST- segment elevation acute coronary syndromes: an ACUITY trial substudy. Catheter Cardiovascular Interv 2015; 85 (1): 1-10.
- Finn A.V, Joner M, Nakazawa G et al. Pathological correlates of late drug - eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115 (18): 2435-41.
- Otsuka F, Nakano M, Ladich E et al. Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement. Thrombosis 2012; 2012: 608593.
- Van Werkum J.W, Heestermans A.A, Zomer A.C et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009; 53 (16): 1399-409.
- Claessen B.E, Henriques J.P, Jaffer F.A et al. Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv 2014; 7 (10): 1081-92.
- Dangas G.D, Claessen B.E, Mehran R et al. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. JACC Cardiovasc Interv 2012; 5 (11): 1097-105.
- Steg P.G, Harrington R.A, Emanuelsson H et al for the P.S.G.Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial. Circulation 2013; 128 (10): 1055-65.
- Gibson C.M, Chakrabarti A.K, Mega J et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol 2013; 62 (4): 286-90.
- Dewilde W.J, Oirbans T, Verheugt F.W et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open - label, randomised, controlled trial. Lancet 2013; 381 (9872): 1107-15.
Дополнительные файлы
